Evidence map›Paper›PMID 27391229›Full record

ArticleBMC urology2016

A positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary prostate biopsy.

Yngve Nygård, Svein A Haukaas, Ole J Halvorsen, Karsten Gravdal, Jannicke Frugård, Lars A Akslen, Christian Beisland

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis.International braz j urol : official journal of the Brazilian Society of Urology
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yngve NygårdDepartment of Urology, Haukeland University Hospital, N-5021, Bergen, Norway. yngve_nygard@yahoo.no.
Svein A HaukaasDepartment of Urology, Haukeland University Hospital, N-5021, Bergen, Norway.
Ole J HalvorsenDepartment of Pathology, Haukeland University Hospital, N-5021, Bergen, Norway.
Karsten GravdalDepartment of Pathology, Haukeland University Hospital, N-5021, Bergen, Norway.
Jannicke FrugårdDepartment of Urology, Haukeland University Hospital, N-5021, Bergen, Norway.
Lars A AkslenDepartment of Pathology, Haukeland University Hospital, N-5021, Bergen, Norway.
Christian BeislandDepartment of Urology, Haukeland University Hospital, N-5021, Bergen, Norway.
University of Bergen · NOHaukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe standard of care in patients with suspected prostate cancer (PCa) is systematic prostate biopsies. This approach leads to unnecessary biopsies in patients without PCa and also to the detection of clinical insignificant PCa. Better tools are wanted. We have evaluated the performance of real-time elastography (RTE) combined with prostate cancer gene 3 (PCA3) in an initial biopsy setting with the goal of better identifying patients in need of prostate biopsies.

methods127 patients were included in this study; three were excluded because of not measureable PCA3 score leading to 124 evaluable patients. A cut-off value of 35 was used for PCA3. All patients were examined with a Hitachi Preirus with an endfire probe for RTE, a maximum of five targeted biopsies were obtained from suspicious lesions detected by RTE. All patients then had a 10-core systematic biopsy performed by another urologist unaware of the RTE results. The study includes follow-up data for a minimum of three years; all available histopathological data are included in the analysis.

resultsThere was a significant difference in PCA3 score: 26.6 for benign disease, 73.6 for cancer patients (p < 0.001). 70 patients (56 %) were diagnosed with prostate cancer in the study period, 21 (30 %) low-risk, 32 (46 %) intermediate-risk and 17 (24 %) high-risk. RTE and PCA3 were significant markers for predicting intermediate- and high-risk PCa (p = 0.001). The combination of RTE and PCA3 had a sensitivity of 96 % and a negative predictive value (NPV) of 90 % for the group of intermediate- and high-risk PCa together and a NPV for high-risk PCa of 100 %. If both parameters are positive there is a high probability of detecting intermediate- or high-risk PCa, if both parameters are negative there is only a small chance of missing prostate cancer with documented treatment benefit.

conclusionsRTE and PCA3 may be used as pre-biopsy examinations to reduce the number of prostate biopsies.

Indexed as

Elasticity Imaging TechniquesAgedAntigens, NeoplasmBiopsy, Large-Core NeedleHumansMaleMiddle AgedProspective StudiesProstateProstatic NeoplasmsRisk AssessmentAntigens, Neoplasmprostate cancer antigen 3, humanDiagnosisPCA3Prostate cancerReal-time elastographyRTEUltrasound

Identifiers

PMID27391229
PMCPMC4938932
OpenAlexW2474281237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.